Concert Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Concert Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Concert Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Concert Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Concert Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Concert Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Concert Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Concert Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Concert Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Concert Pharmaceuticals, Inc. - Brief Concert Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Concert Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Concert Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Concert Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Concert Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Concert Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Concert Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Concert Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Concert Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Concert Pharmaceuticals, Inc. Snapshot
Concert Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Concert Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Concert Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Concert Pharmaceuticals, Inc. – Pipeline Products Glance
Concert Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Concert Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Concert Pharmaceuticals, Inc. – Drug Profiles
C-10003
Product Description
Mechanism of Action
R&D Progress
C-10068
Product Description
Mechanism of Action
R&D Progress
C-10291
Product Description
Mechanism of Action
R&D Progress
C-21191
Product Description
Mechanism of Action
R&D Progress
C-21359
Product Description
Mechanism of Action
R&D Progress
CTP-298
Product Description
Mechanism of Action
R&D Progress
CTP-499
Product Description
Mechanism of Action
R&D Progress
Concert Pharmaceuticals, Inc. – Pipeline Analysis
Concert Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Concert Pharmaceuticals, Inc. - Pipeline Products By Target
Concert Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Concert Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates
Concert Pharmaceuticals, Inc. - Dormant Projects
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CTP 518
Concert Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 31, 2010: Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
Mar 29, 2011: Concert Initiates Phase I Clinical Study Of CTP-499 In Chronic Kidney Disease
Oct 27, 2008: Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential For Once Daily Dosing Of Novel Oxazolidinone Antibiotic, C-20081
Sep 25, 2008: Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial
Sep 25, 2008: Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of CTP-347 And Tamoxifen
Jun 20, 2011: Concert Announces Milestone Achievement In GlaxoSmithKline Collaboration
Jun 20, 2011: Concert Pharmaceuticals Announces Advancement Of C-21191 For Spasticity
Jun 20, 2011: Concert Pharmaceuticals Announces Advancement Of CTP-499 In Kidney Disease
Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting
Oct 19, 2011: Concert Pharmaceuticals To Present Data On Deuterium-Containing GABAA Modulators At Neuroscience 2011
Mar 16, 2009: Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347
Nov 10, 2009: Concert Pharmaceuticals Initiates Phase 1b Clinical Trial Of CTP-518, Protease Inhibitor For Treatment Of HIV
Nov 09, 2009: Concert Pharmaceuticals Initiates Phase Ib Clinical Trial Of CTP-518 For The Treatment Of HIV Infections
May 02, 2011: Concert Pharmaceuticals Presents Preclinical Data On C-10068 At Antiepileptic Drug Trials XI Conference
Financial Deals Landscape
Concert Pharmaceuticals, Inc., Deals Summary
Concert Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Concert Pharmaceuticals Secures $37 Million In Series C Financing
Concert Pharmaceuticals Secures $48.5 Million In Series B Financing
Concert Pharmaceuticals Secures $10 Million In Series A Financing
Partnerships
GlaxoSmithKline Enters Into An Agreement With Concert Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Concert Pharmaceuticals, Inc. - Phase I, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Concert Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Concert Pharmaceuticals, Inc., Deals Summary
Concert Pharmaceuticals Secures $37 Million In Series C Financing
Concert Pharmaceuticals Secures $48.5 Million In Series B Financing
Concert Pharmaceuticals Secures $10 Million In Series A Financing
GlaxoSmithKline Enters Into An Agreement With Concert Pharmaceuticals
LIST OF FIGURES
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Concert Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Concert Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Concert Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Concert Pharmaceuticals, Inc. – Pipeline Products Glance
Concert Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Concert Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Concert Pharmaceuticals, Inc. – Drug Profiles
C-10003
Product Description
Mechanism of Action
R&D Progress
C-10068
Product Description
Mechanism of Action
R&D Progress
C-10291
Product Description
Mechanism of Action
R&D Progress
C-21191
Product Description
Mechanism of Action
R&D Progress
C-21359
Product Description
Mechanism of Action
R&D Progress
CTP-298
Product Description
Mechanism of Action
R&D Progress
CTP-499
Product Description
Mechanism of Action
R&D Progress
Concert Pharmaceuticals, Inc. – Pipeline Analysis
Concert Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Concert Pharmaceuticals, Inc. - Pipeline Products By Target
Concert Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Concert Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates
Concert Pharmaceuticals, Inc. - Dormant Projects
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CTP 518
Concert Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 31, 2010: Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
Mar 29, 2011: Concert Initiates Phase I Clinical Study Of CTP-499 In Chronic Kidney Disease
Oct 27, 2008: Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential For Once Daily Dosing Of Novel Oxazolidinone Antibiotic, C-20081
Sep 25, 2008: Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial
Sep 25, 2008: Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of CTP-347 And Tamoxifen
Jun 20, 2011: Concert Announces Milestone Achievement In GlaxoSmithKline Collaboration
Jun 20, 2011: Concert Pharmaceuticals Announces Advancement Of C-21191 For Spasticity
Jun 20, 2011: Concert Pharmaceuticals Announces Advancement Of CTP-499 In Kidney Disease
Oct 19, 2011: Concert Pharmaceuticals To Present Data On CTP-499 At American Society of Nephrology Kidney Week Meeting
Oct 19, 2011: Concert Pharmaceuticals To Present Data On Deuterium-Containing GABAA Modulators At Neuroscience 2011
Mar 16, 2009: Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347
Nov 10, 2009: Concert Pharmaceuticals Initiates Phase 1b Clinical Trial Of CTP-518, Protease Inhibitor For Treatment Of HIV
Nov 09, 2009: Concert Pharmaceuticals Initiates Phase Ib Clinical Trial Of CTP-518 For The Treatment Of HIV Infections
May 02, 2011: Concert Pharmaceuticals Presents Preclinical Data On C-10068 At Antiepileptic Drug Trials XI Conference
Financial Deals Landscape
Concert Pharmaceuticals, Inc., Deals Summary
Concert Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Concert Pharmaceuticals Secures $37 Million In Series C Financing
Concert Pharmaceuticals Secures $48.5 Million In Series B Financing
Concert Pharmaceuticals Secures $10 Million In Series A Financing
Partnerships
GlaxoSmithKline Enters Into An Agreement With Concert Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Concert Pharmaceuticals, Inc. - Phase I, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Concert Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Concert Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Concert Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Concert Pharmaceuticals, Inc., Deals Summary
Concert Pharmaceuticals Secures $37 Million In Series C Financing
Concert Pharmaceuticals Secures $48.5 Million In Series B Financing
Concert Pharmaceuticals Secures $10 Million In Series A Financing
GlaxoSmithKline Enters Into An Agreement With Concert Pharmaceuticals
LIST OF FIGURES
Concert Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Concert Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Concert Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
